Trials / Unknown
UnknownNCT02188082
Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 336 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Ivabradine acts by inhibiting the ionic If current that modulates the pacemaker activity of sinoatrial node cells. The aim of present study is to evaluate the efficacy and safety of IvabRadine hemisulfate Sustained-release Tablets versus placebo in patients with moderate to severe chronic systolic heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IvabRadine hemisulfate Sustained-release Tablets | |
| DRUG | placebo |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2017-08-01
- First posted
- 2014-07-11
- Last updated
- 2014-07-11
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02188082. Inclusion in this directory is not an endorsement.